Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab High vs Standard Dose in Crohn's Disease
NCT02065570Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2014
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in Crohn's disease (4 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Who Achieved Clinical Remission at 4 weeks, Percentage of Participants With Endoscopic Response at 12 weeks and 1 more. Started May 2014; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02065570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065570.